Midostaurin in FLT3-mutated acute myeloid leukaemia

Lancet Oncol. 2017 Aug;18(8):e439. doi: 10.1016/S1470-2045(17)30506-5. Epub 2017 Jun 29.
No abstract available

Publication types

  • News

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / genetics*
  • Clinical Trials, Phase III as Topic
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / mortality
  • Leukemia, Myeloid, Acute / pathology
  • Mutation*
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Staurosporine / adverse effects
  • Staurosporine / analogs & derivatives*
  • Staurosporine / therapeutic use
  • Treatment Outcome
  • fms-Like Tyrosine Kinase 3 / genetics*

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Protein Kinase Inhibitors
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3
  • Staurosporine
  • midostaurin